| An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment S Drożdżal, J Rosik, K Lechowicz, F Machaj, B Szostak, J Przybyciński, ... Drug Resistance Updates 59, 100794, 2021 | 252 | 2021 |
| Betulin and its derivatives as novel compounds with different pharmacological effects S Amiri, S Dastghaib, M Ahmadi, P Mehrbod, F Khadem, H Behrouj, ... Biotechnology advances 38, 107409, 2020 | 209 | 2020 |
| COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection K Lechowicz, S Drożdżal, F Machaj, J Rosik, B Szostak, ... Journal of clinical medicine 9 (6), 1917, 2020 | 207 | 2020 |
| FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy S Drożdżal, J Rosik, K Lechowicz, F Machaj, K Kotfis, S Ghavami, MJ Łos Drug resistance updates 53, 100719, 2020 | 178 | 2020 |
| Pleiotropic effects of statins: A focus on cancer M Ahmadi, S Amiri, S Pecic, F Machaj, J Rosik, MJ Łos, J Alizadeh, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1866 (12), 165968, 2020 | 111 | 2020 |
| COVID-19: Pain management in patients with SARS-CoV-2 infection—molecular mechanisms, challenges, and perspectives S Drożdżal, J Rosik, K Lechowicz, F Machaj, B Szostak, P Majewski, ... Brain Sciences 10 (7), 465, 2020 | 90 | 2020 |
| Aspirin and its pleiotropic application J Hybiak, I Broniarek, G Kiryczyński, LD Los, J Rosik, F Machaj, ... European journal of pharmacology 866, 172762, 2020 | 89 | 2020 |
| Role of PFKFB3 and PFKFB4 in cancer: genetic basis, impact on disease development/progression, and potential as therapeutic targets K Kotowski, J Rosik, F Machaj, S Supplitt, D Wiczew, K Jabłońska, ... Cancers 13 (4), 909, 2021 | 82* | 2021 |
| The role of genetics and epigenetics in the pathogenesis of gestational diabetes mellitus J Rosik, B Szostak, F Machaj, A Pawlik Annals of human genetics 84 (2), 114-124, 2020 | 66 | 2020 |
| New therapies for the treatment of heart failure: a summary of recent accomplishments F Machaj, E Dembowska, J Rosik, B Szostak, M Mazurek-Mochol, ... Therapeutics and clinical risk management, 147-155, 2019 | 48 | 2019 |
| CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy B Szostak, F Machaj, J Rosik, A Pawlik Expert opinion on investigational drugs 28 (2), 149-159, 2019 | 28 | 2019 |
| Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients B Szostak, F Machaj, J Rosik, A Pawlik Expert Opinion on Drug Metabolism & Toxicology 16 (7), 617-626, 2020 | 26 | 2020 |
| The role of the human microbiome in the pathogenesis of pain K Ustianowska, Ł Ustianowski, F Machaj, A Gorący, J Rosik, B Szostak, ... International Journal of Molecular Sciences 23 (21), 13267, 2022 | 21 | 2022 |
| Potential targets of gene therapy in the treatment of heart failure J Rosik, B Szostak, F Machaj, A Pawlik Expert opinion on therapeutic targets 22 (9), 811-816, 2018 | 21 | 2018 |
| The role of BiP and the IRE1α–XBP1 axis in rhabdomyosarcoma pathology M Aghaei, A Nasimian, M Rahmati, P Kawalec, F Machaj, J Rosik, ... Cancers 13 (19), 4927, 2021 | 11 | 2021 |
| Reprogramming and transdifferentiation-two key processes for regenerative medicine J Hybiak, K Jankowska, F Machaj, J Rosik, I Broniarek, A Żyluk, ... European Journal of Pharmacology 882, 173202, 2020 | 11 | 2020 |
| The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery F Machaj, J Rosik, B Szostak, A Pawlik Expert Opinion on Drug Discovery 15 (1), 85-99, 2020 | 11 | 2020 |
| Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatment strategies A Zarrabi, D Perrin, M Kavoosi, M Sommer, S Sezen, P Mehrbod, ... Cancers 15 (21), 5269, 2023 | 7 | 2023 |
| The role of CTLA4 and its polymorphisms in solid organ and haematopoietic stem cell transplantation J Rosik, B Szostak, F Machaj, A Pawlik International Journal of Molecular Sciences 22 (6), 3081, 2021 | 4 | 2021 |
| Improving mitochondrial function in preclinical models of heart failure: Therapeutic targets for future clinical therapies? A Gorący, J Rosik, J Szostak, B Szostak, S Retfiński, F Machaj, A Pawlik Expert Opinion on Therapeutic Targets 27 (7), 593-608, 2023 | 2 | 2023 |
